$3.97
0.75% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Opthea Limited - ADR Stock price

$3.97
+1.03 35.03% 1M
+0.06 1.53% 6M
+1.02 34.58% YTD
+2.24 129.48% 1Y
-3.82 49.04% 3Y
-16.85 80.94% 5Y
+2.57 183.57% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.03 0.75%
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Key metrics

Market capitalization $615.54m
Enterprise Value $643.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4,951.54
P/S ratio (TTM) P/S ratio 4,734.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 15.94%
Revenue (TTM) Revenue $130.00k
EBIT (operating result TTM) EBIT $-192.66m
Free Cash Flow (TTM) Free Cash Flow $-160.97m
EPS (TTM) EPS $-2.67
P/E forward negative
P/S forward 84.43
EV/Sales forward 88.29
Short interest 0.06%
Show more

Is Opthea Limited - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Opthea Limited - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Opthea Limited - ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Opthea Limited - ADR forecast:

Buy
86%
Hold
14%

Financial data from Opthea Limited - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
0.13 0.13
18% 18%
100%
- Direct Costs 0.10 0.10
-
77%
0.02 0.02
-
15%
- Selling and Administrative Expenses 16 16
44% 44%
12,031%
- Research and Development Expense 177 177
46% 46%
136,108%
-193 -193
-
-148,123%
- Depreciation and Amortization 0.10 0.10
-
77%
EBIT (Operating Income) EBIT -193 -193
29% 29%
-148,203%
Net Profit -221 -221
56% 56%
-169,946%

In millions USD.

Don't miss a Thing! We will send you all news about Opthea Limited - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Opthea Limited - ADR Stock News

Neutral
GlobeNewsWire
10 days ago
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Neutral
GlobeNewsWire
18 days ago
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch ...
Neutral
GlobeNewsWire
23 days ago
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical Company developing novel therapi...
More Opthea Limited - ADR News

Company Profile

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Head office Australia
CEO Frédéric Guerard
Founded 1984
Website www.opthea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today